Company registration number 13765826 (England and Wales)
BIOFARM LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2025
PAGES FOR FILING WITH REGISTRAR
BIOFARM LIMITED
CONTENTS
Page
Balance sheet
1
Statement of changes in equity
2
Notes to the financial statements
3 - 7
BIOFARM LIMITED
BALANCE SHEET
AS AT
30 NOVEMBER 2025
30 November 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
4
7,439
4,557
Current assets
Debtors
5
70,006
20,700
Cash at bank and in hand
134,417
176,399
204,423
197,099
Creditors: amounts falling due within one year
6
(1,611,268)
(862,003)
Net current liabilities
(1,406,845)
(664,904)
Net liabilities
(1,399,406)
(660,347)
Capital and reserves
Called up share capital
7
2
2
Profit and loss reserves
(1,399,408)
(660,349)
Total equity
(1,399,406)
(660,347)

For the financial year ended 30 November 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 17 June 2026 and are signed on its behalf by:
Mr A A Brainin
Director
Company registration number 13765826 (England and Wales)
BIOFARM LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 2 -
Share capital
Capital redemption reserve
Profit and loss reserves
Total
Notes
£
£
£
£
Balance at 1 December 2023
2
-
0
(199,527)
(199,525)
Year ended 30 November 2024:
Loss for the year
-
-
(460,822)
(460,822)
Balance at 30 November 2024
2
-
0
(660,349)
(660,347)
Year ended 30 November 2025:
Loss for the year
-
-
(739,059)
(739,059)
Balance at 30 November 2025
2
-
0
(1,399,408)
(1,399,406)
BIOFARM LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 3 -
1
Accounting policies
Company information

Biofarm Limited is a private company limited by shares incorporated in England and Wales. The registered office is 82 St John Street, London, EC1M 4JN.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

As at the balance sheet date, the financial statements show that the company has liabilities in excess of assets of £1,399,406 (202 4: £660,346) as a result of losses made to date. The financial statements have been prepared on a going concern basis as the directors have confirmed that they will continue to support the company for the foreseeable future and meet the excess liabilities if the company is unable to do so.

1.3
Turnover

Turnover represents amounts receivable for services provided in relation to leasing of land and monitoring of Offsite Biodiversity Net G ain habit at units. These amounts are recognised in the period in which the service is provided.

1.4
Research and development expenditure

Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.

1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings
25% on cost
Computer equipments
25% on cost

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand and deposits held at call with banks.

BIOFARM LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
1
Accounting policies
(Continued)
- 4 -
1.7
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future paymen ts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. A m ounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.8
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.9
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

1.10
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.11
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the lease s asset are consumed.

BIOFARM LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
1
Accounting policies
(Continued)
- 5 -
1.12
Government grants

Government grants are recognised at the fair value of the asset receive d or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
9
7
3
Government grants
Included within operating income are government grants as follow:
2025
2024
£
£
Basic Payment Scheme (BPS) Grant
1,144
7,029
NERF3067 Claim 1 Grant
51,017
12,192
52,161
19,221
BIOFARM LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 6 -
4
Tangible fixed assets
Fixtures and fittings
Computer equipments
Total
£
£
£
Cost
At 1 December 2024
-
0
5,570
5,570
Additions
3,053
2,030
5,083
At 30 November 2025
3,053
7,600
10,653
Depreciation and impairment
At 1 December 2024
-
0
1,013
1,013
Depreciation charged in the year
403
1,798
2,201
At 30 November 2025
403
2,811
3,214
Carrying amount
At 30 November 2025
2,650
4,789
7,439
At 30 November 2024
-
0
4,557
4,557
5
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
16,168
-
0
Other debtors
53,838
20,700
70,006
20,700
6
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
29,985
15,413
Taxation and social security
10,653
7,556
Other creditors
1,570,630
839,034
1,611,268
862,003
BIOFARM LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 7 -
7
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of 0.01p each
20,000
20,000
2
2
Ordinary B shares of 0.01p each
440
440
-
0
-
0

On 15 July 2025, 220 Ordinary B shares of £0.0001 each were issued at par.

On 13 August 2025, the company b rought back 220 Ordinary B shares of £0.0001 each.

8
Related party transactions

Included within other creditors is an amount of £200,000 (2024: £Nil) owed to South Hill Capital Limited, a related company by virtue of common control. The loan is interest free and repayable on demand.

9
Directors' transactions

Included within other creditors is a balance of £1,200,03 7 (2024: £800,055) owed to directors. The loan is interest free and repayable on demand.

2025-11-30 2024-12-01 false false false 18 June 2026 CCH Software CCH Accounts Production 2026.100 No description of principal activity Mr A A Brainin Mr P P Brainin Mr S D Nash Mr D Woodfield 13765826 2024-12-01 2025-11-30 13765826 2025-11-30 13765826 2024-11-30 13765826 core:FurnitureFittings 2025-11-30 13765826 core:ComputerEquipment 2025-11-30 13765826 core:FurnitureFittings 2024-11-30 13765826 core:ComputerEquipment 2024-11-30 13765826 core:CurrentFinancialInstruments core:WithinOneYear 2025-11-30 13765826 core:CurrentFinancialInstruments core:WithinOneYear 2024-11-30 13765826 core:Non-currentFinancialInstruments 2025-11-30 13765826 core:Non-currentFinancialInstruments 2024-11-30 13765826 core:ShareCapital 2025-11-30 13765826 core:ShareCapital 2024-11-30 13765826 core:RetainedEarningsAccumulatedLosses 2025-11-30 13765826 core:RetainedEarningsAccumulatedLosses 2024-11-30 13765826 core:ShareCapital 2023-11-30 13765826 core:CapitalRedemptionReserve 2023-11-30 13765826 core:RetainedEarningsAccumulatedLosses 2023-11-30 13765826 core:CapitalRedemptionReserve 2024-11-30 13765826 core:CapitalRedemptionReserve 2025-11-30 13765826 core:ShareCapitalOrdinaryShareClass1 2025-11-30 13765826 core:ShareCapitalOrdinaryShareClass1 2024-11-30 13765826 core:ShareCapitalOrdinaryShareClass2 2025-11-30 13765826 core:ShareCapitalOrdinaryShareClass2 2024-11-30 13765826 bus:Director1 2024-12-01 2025-11-30 13765826 core:RetainedEarningsAccumulatedLosses 2023-12-01 2024-11-30 13765826 2023-12-01 2024-11-30 13765826 core:RetainedEarningsAccumulatedLosses 2024-12-01 2025-11-30 13765826 core:FurnitureFittings 2024-12-01 2025-11-30 13765826 core:ComputerEquipment 2024-12-01 2025-11-30 13765826 core:FurnitureFittings 2024-11-30 13765826 core:ComputerEquipment 2024-11-30 13765826 2024-11-30 13765826 core:CurrentFinancialInstruments 2025-11-30 13765826 core:CurrentFinancialInstruments 2024-11-30 13765826 bus:OrdinaryShareClass1 2025-11-30 13765826 bus:OrdinaryShareClass1 2024-11-30 13765826 bus:OrdinaryShareClass2 2025-11-30 13765826 bus:OrdinaryShareClass2 2024-11-30 13765826 bus:OrdinaryShareClass2 2024-12-01 2025-11-30 13765826 bus:PrivateLimitedCompanyLtd 2024-12-01 2025-11-30 13765826 bus:SmallCompaniesRegimeForAccounts 2024-12-01 2025-11-30 13765826 bus:FRS102 2024-12-01 2025-11-30 13765826 bus:AuditExemptWithAccountantsReport 2024-12-01 2025-11-30 13765826 bus:Director2 2024-12-01 2025-11-30 13765826 bus:Director3 2024-12-01 2025-11-30 13765826 bus:Director4 2024-12-01 2025-11-30 13765826 bus:FullAccounts 2024-12-01 2025-11-30 xbrli:pure xbrli:shares iso4217:GBP